New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
09:02 EDTSNY, INWKSanofi, InnerWorkings sign global marketing partnership
InnerWorkings (INWK) has been selected as a global marketing partner of Sanofi (SNY). Under this agreement, InnerWorkings will oversee the creation, production, and management of Sanofiís worldwide promotional items, with a special focus on implementing high standards for corporate and social responsibility across global operations. Additionally, InnerWorkings will drive enhanced innovation, stewardship, and consistency across Sanofiís global efforts. InnerWorkings and Sanofi began its partnership in 2013 with a pilot program to support Sanofiís work in 15 countries across the Americas, Europe and Africa. Throughout the rest of 2014, InnerWorkings will expand this solution to dozens more countries and regions.
News For SNY;INWK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
16:01 EDTSNYSanofi subsidiary to pay $32.5M to resolve Seprafilm 'criminal liability'
Subscribe for More Information
September 2, 2015
14:47 EDTINWKInnerWorkings management to meet with Craig-Hallum
Subscribe for More Information
September 1, 2015
16:17 EDTSNYArdelyx regains NaP2b program from Sanofi
Subscribe for More Information
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
August 31, 2015
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use